Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR014 + Durvalumab in R/R B-cell NHL
NCT02706405Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2016
- Primary completion
- May 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Antibody Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of JCAR014 and durvalumab in B-cell non-Hodgkin lymphoma, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Count of Participants Who Experienced Adverse Events at 1 year, Dose Limiting Toxicity (DLT) Rates at 28 days and 3 more. Started Nov 2016; status: terminated.
02
Drugs
JCAR014durvalumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02706405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706405.